Connection

Co-Authors

This is a "connection" page, showing publications co-authored by IZABELA FOKT and WALDEMAR PRIEBE.
Connection Strength

3.638
  1. d-Glucose- and d-mannose-based antimetabolites. Part 4: Facile synthesis of mono- and di-acetates of 2-deoxy-d-glucose prodrugs as potentially useful antimetabolites. Carbohydr Res. 2023 Sep; 531:108861.
    View in: PubMed
    Score: 0.899
  2. D-Glucose and D-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated D-glucose, D-mannose, and 2-deoxy-D-glucose. Carbohydr Res. 2013 Mar 07; 368:111-9.
    View in: PubMed
    Score: 0.435
  3. D-glucose- and D-mannose-based antimetabolites. Part 2. Facile synthesis of 2-deoxy-2-halo-D-glucoses and -D-mannoses. Carbohydr Res. 2009 Aug 17; 344(12):1464-73.
    View in: PubMed
    Score: 0.342
  4. The Antiviral Effects of 2-Deoxy-D-glucose (2-DG), a Dual D-Glucose and D-Mannose Mimetic, against SARS-CoV-2 and Other Highly Pathogenic Viruses. Molecules. 2022 Sep 12; 27(18).
    View in: PubMed
    Score: 0.214
  5. Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation. Invest New Drugs. 2017 Oct; 35(5):545-555.
    View in: PubMed
    Score: 0.147
  6. A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemother Pharmacol. 2011 Oct; 68(4):1033-44.
    View in: PubMed
    Score: 0.096
  7. Preclinical evaluation of new anthracyclines. Curr Med Chem. 2001 Jan; 8(1):9-13.
    View in: PubMed
    Score: 0.095
  8. Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Arch Immunol Ther Exp (Warsz). 2007 May-Jun; 55(3):193-8.
    View in: PubMed
    Score: 0.074
  9. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells". Cancer Chemother Pharmacol. 2006 Dec; 58(6):725-34.
    View in: PubMed
    Score: 0.068
  10. Topoisomerase II alpha expression and cytotoxicity of anthracyclines in human neoplastic cells. Acta Pol Pharm. 2006 Jan-Feb; 63(1):15-8.
    View in: PubMed
    Score: 0.067
  11. Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells. Anticancer Res. 2005 May-Jun; 25(3B):2193-8.
    View in: PubMed
    Score: 0.064
  12. Constitutive activation of transcription factor NFkappaB as a possible marker of sensitivity of neoplastic cells to anthracyclines. Acta Pol Pharm. 2005 Jan-Feb; 62(1):17-23.
    View in: PubMed
    Score: 0.063
  13. Potent Biological Activity of Fluorinated Derivatives of 2-Deoxy-d-Glucose in a Glioblastoma Model. Biomedicines. 2024 Oct 01; 12(10).
    View in: PubMed
    Score: 0.062
  14. Sequence selective binding of bis-daunorubicin WP631 to DNA. Eur J Biochem. 2004 Sep; 271(17):3556-66.
    View in: PubMed
    Score: 0.061
  15. Differential toxic effect of cis-platinum(II) and palladium(II) chlorides complexed with methyl 3,4-diamine-2,3,4,6-tetradeoxy-alpha-L-lyxo-hexopyranoside in mouse lymphoma cell lines differing in DSB and NER repair ability. Teratog Carcinog Mutagen. 2003; Suppl 1:1-11.
    View in: PubMed
    Score: 0.055
  16. Correction: X-ray wavefunction refinement and comprehensive structural studies on bromo-substituted analogues of 2-deoxy-d-glucose in solid state and solution. RSC Adv. 2022 Mar 31; 12(17):10306.
    View in: PubMed
    Score: 0.052
  17. X-ray wavefunction refinement and comprehensive structural studies on bromo-substituted analogues of 2-deoxy-d-glucose in solid state and solution. RSC Adv. 2022 03 15; 12(14):8345-8360.
    View in: PubMed
    Score: 0.052
  18. Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model. Biomedicines. 2021 Nov 23; 9(12).
    View in: PubMed
    Score: 0.051
  19. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res. 2001 Nov-Dec; 21(6A):3777-84.
    View in: PubMed
    Score: 0.050
  20. Experimental and Computational Studies on Structure and Energetic Properties of Halogen Derivatives of 2-Deoxy-D-Glucose. Int J Mol Sci. 2021 Apr 02; 22(7).
    View in: PubMed
    Score: 0.048
  21. Exploiting anthracycline scaffold for designing DNA-targeting agents. Methods Enzymol. 2001; 340:529-55.
    View in: PubMed
    Score: 0.047
  22. Drug Conjugates for Targeting Eph Receptors in Glioblastoma. Pharmaceuticals (Basel). 2020 Apr 23; 13(4).
    View in: PubMed
    Score: 0.045
  23. Novel Molecular Multilevel Targeted Antitumor Agents. Cancer Transl Med. 2017 May-Jun; 3(3):69-79.
    View in: PubMed
    Score: 0.037
  24. Structure-based design of a new bisintercalating anthracycline antibiotic. J Med Chem. 1997 Jan 31; 40(3):261-6.
    View in: PubMed
    Score: 0.036
  25. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst. 2016 12; 108(12).
    View in: PubMed
    Score: 0.035
  26. Parsing the free energy of anthracycline antibiotic binding to DNA. Biochemistry. 1996 Feb 20; 35(7):2047-53.
    View in: PubMed
    Score: 0.034
  27. Development of novel molecular probes of the Rio1 atypical protein kinase. Biochim Biophys Acta. 2013 Jul; 1834(7):1292-301.
    View in: PubMed
    Score: 0.028
  28. Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells. Cancer Biol Ther. 2012 Jun; 13(8):657-70.
    View in: PubMed
    Score: 0.026
  29. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. J Neurooncol. 2012 May; 107(3):487-501.
    View in: PubMed
    Score: 0.026
  30. Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms. PLoS One. 2011; 6(9):e24397.
    View in: PubMed
    Score: 0.025
  31. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One. 2011 Jan 20; 6(1):e16195.
    View in: PubMed
    Score: 0.024
  32. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer. 2011 Jul 01; 117(13):2926-38.
    View in: PubMed
    Score: 0.024
  33. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res. 2010 May 01; 16(9):2550-61.
    View in: PubMed
    Score: 0.023
  34. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother. 2009 Jul; 58(7):1023-32.
    View in: PubMed
    Score: 0.020
  35. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res. 2008 Sep 15; 14(18):5759-68.
    View in: PubMed
    Score: 0.020
  36. Complexation of metal ions in Langmuir films formed with two amphiphilic dioxadithia crown ethers. J Phys Chem B. 2008 Sep 04; 112(35):10953-63.
    View in: PubMed
    Score: 0.020
  37. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007 Oct 15; 67(20):9630-6.
    View in: PubMed
    Score: 0.019
  38. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Invest New Drugs. 2007 Aug; 25(4):313-26.
    View in: PubMed
    Score: 0.018
  39. WP760, a melanoma selective drug. Cancer Chemother Pharmacol. 2007 Oct; 60(5):625-33.
    View in: PubMed
    Score: 0.018
  40. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem Pharmacol. 2007 Mar 01; 73(5):620-31.
    View in: PubMed
    Score: 0.018
  41. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene. 2007 Apr 12; 26(17):2435-44.
    View in: PubMed
    Score: 0.018
  42. A new bisintercalating anthracycline with picomolar DNA binding affinity. J Med Chem. 2005 Dec 29; 48(26):8209-19.
    View in: PubMed
    Score: 0.017
  43. A bisanthracycline (WP631) represses uPAR gene expression and cell migration of RKO colon cancer cells by interfering with transcription factor binding to a chromatin-accessible -148/-124 promoter region. Oncol Res. 2005; 15(5):265-79.
    View in: PubMed
    Score: 0.016
  44. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem Pharmacol. 2004 Jan 15; 67(2):353-64.
    View in: PubMed
    Score: 0.015
  45. Preferential efflux by P-glycoprotein, but not MRP1, of compounds containing a free electron donor amine. Biochem Pharmacol. 2002 Apr 15; 63(8):1471-9.
    View in: PubMed
    Score: 0.013
  46. Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action. Curr Med Chem. 2001 Jan; 8(1):51-64.
    View in: PubMed
    Score: 0.012
  47. Allosteric, chiral-selective drug binding to DNA. Proc Natl Acad Sci U S A. 2000 Oct 24; 97(22):12032-7.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.